Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches. Our team of researchers and leading scientific collaborators understand the unique needs of microRNA-based therapeutics development: identifying valid, ‘druggable’ targets and applying pharmacology and translational biology to optimize therapies with the greatest chance of clinical success.